Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bliss

Showing results (341-350 of 378) with videos related to

Pageof 38
Sort By:
Antimicrobial Agents and Chemotherapy|September 19, 2025
Metronidazole exposure-response and safety in infantsRachel L Randell, Stephen J Balevic, Rachel G Greenberg, et al.
Health Technology Assessment (Winchester, England)|November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Nature Communications|November 10, 2016
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationPascal Gellert, Corrinne V Segal, Qiong Gao, et al.
Lancet (London, England)|June 26, 2020
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
Nature Communications|April 24, 2021
Genomic profile of advanced breast cancer in circulating tumour DNABelinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
The Lancet. Oncology|March 22, 2008
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Frontiers in Immunology|December 8, 2017
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled TrialVictorine A Mensah, Sophie Roetynck, Ebrima K Kanteh, et al.
Pageof 38

Showing results (341-350 of 378) with videos related to

Sort By:
Pageof 38
Antimicrobial Agents and Chemotherapy|September 19, 2025
Metronidazole exposure-response and safety in infantsRachel L Randell, Stephen J Balevic, Rachel G Greenberg, et al.
Health Technology Assessment (Winchester, England)|November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Nature Communications|November 10, 2016
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationPascal Gellert, Corrinne V Segal, Qiong Gao, et al.
Lancet (London, England)|June 26, 2020
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
Nature Communications|April 24, 2021
Genomic profile of advanced breast cancer in circulating tumour DNABelinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
The Lancet. Oncology|March 22, 2008
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, S M Bentzen, R K Agrawal, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Frontiers in Immunology|December 8, 2017
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled TrialVictorine A Mensah, Sophie Roetynck, Ebrima K Kanteh, et al.
Pageof 38